Stock Ratings / Health Care / BOLT / dividends

HIND (35) KTTA (44) BIVI (33) LPCN (37) ⌘ Pro Terminal →

Bolt Biotherapeutics Inc. (BOLT) Dividend Safety Gauge & 10-Year DRIP Compounder

$6.36 -3.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.31

Bolt Biotherapeutics Inc. (BOLT) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $12.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.31 (-0.79%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-13.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BOLT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (28/100 Composite)

🔍 WHY BOLT SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (29% of score)

FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 75.2 (OVERBOUGHT (>70))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$4.11-2.7% Next Q

Q2 (-2Q)

Grade E$4.00+56.7% Next Q

Q3 (-1Q)

Grade E$6.27+1.4% Next Q

Current

Grade E$6.36-10% Hist 90D α

Trajectory: E (20) → E (28)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BOLT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BOLT currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.14) and Max Pain ($6.68) forces dealer call-delta covering toward $8.17.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BOLT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BOLT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 28%NO 72%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BOLT)

✓Walkthrough of BOLT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BOLT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +32.50%📐 HORIZONTAL RANGE

2026-10-30O $6.28H $6.59L $6.09C $6.36VOL 249.9K

RES: $7.88SUP: $3.07SMA50: $4.14SMA200: $4.51

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BOLT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BOLT Butterfly Map → + Track BOLT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +0.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BOLT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BOLT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BOLT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BOLT)

Health Care Rank #972 of 1016 ⚔️ HIND vs BOLT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BOLT vs. HIND, KTTA, BIVI, LPCN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bolt Biotherapeutics Inc. (BOLT) ranks #972 by composite RQD confidence (28/100, grade E) and #877 by equity capitalization ($12.3M). Within this direct 5-issuer industry benchmark cohort, BOLT leads on earnings valuation at N/A trailing P/E, while BOLT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KTTA currently holds the highest overall quantitative score in the immediate peer group at 44/100 (D) compared with BOLT at 28/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BOLT ACTIVE Bolt Biotherapeutics Inc.	E	28/100	—	—	-35.0%	-3.34%	$12.3M	Benchmark Subject
HIND Vyome Holdings Inc.	D-	35/100	—	68.4%	-35.0%	+1.74%	$12.3M	/hind-vs-bolt →
KTTA Pasithea Therapeutics Corp.	D	44/100	—	—	-35.0%	-5.95%	$12.3M	/ktta-vs-bolt →
BIVI BioVie Inc. (Class A)	E	33/100	—	—	-35.0%	-5.48%	$12.0M	/bivi-vs-bolt →
LPCN Lipocine Inc.	D-	37/100	—	—	-35.0%	+0.66%	$12.5M	/lpcn-vs-bolt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001641281

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bolt Biotherapeutics Inc. (BOLT) reported GAAP revenue of $7.7M (+0.1% vs. FY2024 revenue of $7.7M , and -2.3% cumulative change since FY2023) , GAAP net income of -$33.4M, operating cash flow of -$39.9M, and free cash flow of -$39.9M (+34.9% YoY). On the balance sheet, BOLT closed FY2025 with $56.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$7.7M	-$33.4M	-$39.9M	-$39.9M	$56.7M	—
FY2024 (FY)	2024-12-31	$7.7M	-$63.1M	-$61.3M	-$61.3M	$99.6M	—
FY2023 (FY)	2023-12-31	$7.9M	-$69.2M	-$69.5M	-$69.5M	—	—

3. BOLT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BOLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Bolt Biotherapeutics Inc. (NASDAQ: BOLT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $6.36 (-3.34% 1D, market cap $12.3M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BOLT ranks #972 in composite RQD confidence.

How does BOLT compare to HIND and KTTA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLT carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HIND (Vyome Holdings Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M) and KTTA (Pasithea Therapeutics Corp.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $12.3M). Among the 5-stock peer group, BOLT leads on earnings multiple (N/A) while BOLT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BOLT?

Per BOLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001641281), Bolt Biotherapeutics Inc. generated $7.7M in revenue (+0.1% YoY), -$33.4M in net income, and -$39.9M in free cash flow against $56.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BOLT trading relative to its 50-day, 200-day, and 52-week technical levels?

BOLT last traded at $6.36 (-3.34% on volume of 76,274 shares), positioning the stock +53.62% above its 50-day simple moving average ($4.14) and +41.02% above its 200-day simple moving average ($4.51). Across its 52-week range of $3.10 to $7.78, BOLT sits at the 69.7% percentile with a 14-day RSI of 75.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($5.56 to $7.16).

BOLT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does BOLT pay a dividend and is it safe?

Bolt Biotherapeutics Inc. (BOLT) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: BOLT RQD Cockpit BOLT 12M Forecast BOLT Earnings & Move BOLT Dividends & DRIP BOLT Insiders & 13F BOLT Whale Options BOLT Profit Sankey BOLT News & Why